The unnamed drug is aimed at patients with Friedreich's Ataxia - an inherited disease that causes progressive damage to the nervous system. It is characterized by problems with balance, coordination and speech.
F-H was awarded the account following a three-way pitch. It is charged with rolling out a European comms programme for the drug, whose compound is called high-dose idebenone.
Friedreich's Ataxia is rare but is the most prevalent inherited ataxia, affecting about one in every 50,000. Symptoms usually begin between the ages of five and 15.
F-H's comms programme will target patients and their parents across Europe. The agency's healthcare practice will also provide affiliates with strategies and media tools to launch the product.
F-H to promote unnamed drug
Gemma O'Reilly, PR Week UK, 15 May 2008, 06:00am
Be the first to comment
Japanese pharma firm Takeda has brought on board Fleishman-Hillard to handle PR support for a pre-launch drug.
Takeda: F-H hire
Tags:
All Comments
There are currently no comments.
To post comments please log in here
- Head of Press, Youth Sport Trust
- c.£45k + Benefits, Central London
- Senior Account Executives & Account Managers, Sterling Communications
- Competitive, Central London
- Senior Account Manager / Account Director, Blue Communications
- £45-55,000 based on experience, Asia
- Senior Account Director / Associate (Personal Finance), Media Contacts
- £55000 to £70000 Per: annum, Central London
- CORPORATE COMMUNICATIONS MANAGER, JFL Search & Selection
- Circa £45K, Central London
PRWeek Agency Showcase
Bulletins
You can sign up for our bulletins. Select bulletins you are interested in, enter your email adress an click the button below
Poll
PR Week Poll Sponsored By:
_rgb.jpg "YouGov")
Latest Issue
Issue 03/07/09
- Danny Rogers: Lessons can be gained from integration
Profile on Nick Sharples, European comms chief, Sony
- Profile on Biz Stone, co-founder, Twitter
Comments